A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Zanubrutinib (Primary) ; Obinutuzumab
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeiGene
- 15 Dec 2017 Planned number of patients changed from 86 to 132.
- 15 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Feb 2019.
- 15 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Feb 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History